Onconetix Inc（ONCO）の株式分析

$0.612

-0.019 (-3.12%)終値時点

Loading chart…

High: 0.644
Open: 0.628
VWAP: 0.62
Vol: 91.48K
Mkt Cap: —
Low: 0.610
Amount: 56.90K
EV/EBITDA, TTM: 0.00

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

www.onconetix.com

AI analysis of Onconetix Inc (ONCO)

sell

Onconetix Inc (ONCO) is not a good buy right now due to its extremely low current price of $0.61, a year-to-date change of -99.24%, and a very low RSI of 16.50, indicating oversold conditions. The company has also reported significant losses, with a net income of -2,867,303 in Q2 2026 and a gross margin of only 25.13%. The primary risk is the potential for further declines given the stock's volatility and the recent reverse stock split aimed at maintaining compliance with Nasdaq listing requirements.

バリュエーション指標

The current forward P/E ratio for Onconetix Inc (ONCO) is 0.00, compared to its 5-year average forward P/E of -2.37.

Forward P/E

Fair

5Y Average P/E

-2.37

Current P/E

0.00

割高

6.01

割安

-10.75

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-2.41

Current EV/EBITDA

0.00

割高

7.09

割安

-11.91

Forward P/S

Fair

5Y Average P/S

10.45

Current P/S

0.00

割高

50.72

割安

-29.82

Alphio AI Price Scenarios for ONCO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%ONCO

$4.05

シナリオ価格

Base

Base · 50%ONCO

$3.96

シナリオ価格

Bear

Bear · 25%ONCO

$3.95

シナリオ価格

イベントタイムライン

2026-08-12 (ET)